A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/Refractory Multiple Myeloma

BACKGROUND: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHODS: The current study was a multicenter study with...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer
Hoofdauteurs: Chari, Ajai, Htut, Myo, Zonder, Jeffrey A., Fay, Joseph W., Jakubowiak, Andrzej J., Levy, Joan B., Lau, Kenneth, Burt, Steven M., Tunquist, Brian J., Hilder, Brandi W., Rush, Selena A., Walker, Duncan H., Ptaszynski, Mieke, Kaufman, Jonathan L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857452/
https://ncbi.nlm.nih.gov/pubmed/27433944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30174
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items